Xtalks Featured Member: Lavanya Ramnath, Senior Regulatory Affairs Specialist, Insulet

We’re proud to present Xtalks Featured Community Member Lavanya Ramnath, whose regulatory leadership has supported medical devices from clinical development through global approvals. Read how she serves as the regulatory lead for both clinical trials and commercialization, authoring IDEs, supplements, 510(k)s and managing FDA communications to ensure timely approvals.

What Are Your Proudest Life Science Achievements?

My proudest achievements center on leading regulatory strategy for complex, high-risk medical devices across their full product lifecycle, ensuring that innovation directly translates into patient access and regulatory success.

• FDA Clearance in Record Time: I co‑authored and supported FDA clearance of a traditional 510(k) in just 66 days for an indication expansion of Omnipod 5, making it the first automated insulin delivery system that was FDA-cleared for both type 1 and type 2 diabetes.
• EU MDR Success: Earlier in my career, I led EU MDR regulatory strategy and submission for a Class III balloon dilatation catheter, achieving CE Mark and UKCA approval within 13 months.
• Breakthrough Devices Program: I led regulatory strategy and submission to support clinical studies for Insulet’s next‑generation automated insulin delivery (AID) programs — including both hybrid and fully closed‑loop systems with FDA Breakthrough Device designation. I authored three original IDE submissions and five IDE supplements, all of which received FDA approval within 30 calendar days. I contributed to a modular PMA submission under the FDA’s Breakthrough Devices Program, enabling Abbott to market the first‑of‑its‑kind resorbable scaffold.
• Global Market Access: At Abbott, I led regulatory strategy and submissions across 50+ countries in Asia Pacific, Latin America and Emerging Markets. Partnering closely with in‑country RA experts, I spearheaded approvals and launches for Abbott’s cardiovascular portfolio.

Together, these milestones reflect my ability to drive regulatory innovation under tight timelines, navigate global frameworks and ultimately expand access to transformative therapies for patients worldwide.

What Are Your Day-to-Day Job Highlights?

In my current role at Insulet, my day-to-day work focuses on developing regulatory strategy and submissions for clinical development and premarket submissions — supporting enhancements to Insulet’s existing automated insulin delivery systems as well as development of next-generation fully closed-loop insulin pumps.

I serve as the regulatory lead for both clinical trials and commercialization, authoring IDEs, supplements, 510(k)s and managing FDA communications to ensure timely approvals. I work closely with the cross-functional partners — software, systems, algorithms, clinical and quality teams — to name a few. I particularly enjoy translating complex software and algorithm-driven functionality into clear, defensible regulatory narratives that regulators can readily assess.

A rewarding part of my role is mentoring colleagues and early-career professionals, helping them understand not just what regulatory requirements exist, but why they matter in enabling patient access to innovation.

What Are Your Favorite Life Science Innovations?

I’m especially energized by innovations at the intersection of software, automation and chronic disease management, particularly in digital health and SaMD-enabled medical devices.

Automated insulin delivery systems exemplify how sophisticated algorithms, real-time sensing and human-factors-driven design can meaningfully improve patient outcomes, but only when supported by thoughtful regulatory frameworks. I’m fascinated by how regulators are evolving expectations around software updates, cybersecurity, real-world evidence and adaptive systems, and how these concepts are being operationalized in real submissions.

For me, this space represents the future of life sciences: where technology, patient needs and regulatory science converge to deliver safer, smarter and more accessible therapies.

What Is Your Vision for the Future of the Industry?

I believe the future of life sciences depends on regulatory systems that evolve alongside technology, rather than lag behind it.

As medical devices become more software-driven and interconnected, regulatory frameworks must support continuous innovation, iterative updates and global scalability; without diluting safety or scientific rigor. I see a future where regulators, manufacturers and clinicians collaborate earlier and more transparently, supported by clearer expectations around software lifecycle management, cybersecurity and real-world performance monitoring.

Equally important is the future of the regulatory profession itself. Regulatory affairs should be recognized not as a downstream function, but as a strategic enabler of innovation, grounded in science, risk management and patient impact. I’m passionate about mentoring and contributing to professional communities like RAPS to help build that future where regulatory expertise accelerates access to life-changing technologies worldwide.

Apply Yourself or Nominate a Peer

Do you know someone doing incredible work in the life sciences? Or perhaps you’re proud of your own journey and want to inspire others? We’d love to hear from you.

You can apply to be an Xtalks Featured Community Member or nominate a colleague through our simple online form. It takes just a few minutes, and it could open doors to new conversations, partnerships and recognition across the industry.

Let’s celebrate the people driving life sciences forward, one story at a time.